Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
The European and Japanese patent applications have been accepted and, once granted, are expected to be valid until 2034 U.S. NDA for Talicia® on track for potential submission in H1/2019 and U.S....
-
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 26, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 20, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
TEL-AVIV, Israel and RALEIGH, N.C., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034NDA submission is expected in H1/2019, with eligibility for 6-month priority review; Subject to...
-
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
-
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical...
-
TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty...
-
The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance (p<0.0001) High resistance to...